Cargando…
One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
BACKGROUND: Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The interrelated methionine, purine, and thymidylate cycles constitute the one-carbon...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473969/ https://www.ncbi.nlm.nih.gov/pubmed/28623948 http://dx.doi.org/10.1186/s13195-017-0270-x |
_version_ | 1783244384187187200 |
---|---|
author | Dayon, Loïc Guiraud, Seu Ping Corthésy, John Da Silva, Laeticia Migliavacca, Eugenia Tautvydaitė, Domilė Oikonomidi, Aikaterini Moullet, Barbara Henry, Hugues Métairon, Sylviane Marquis, Julien Descombes, Patrick Collino, Sebastiano Martin, François-Pierre J. Montoliu, Ivan Kussmann, Martin Wojcik, Jérôme Bowman, Gene L. Popp, Julius |
author_facet | Dayon, Loïc Guiraud, Seu Ping Corthésy, John Da Silva, Laeticia Migliavacca, Eugenia Tautvydaitė, Domilė Oikonomidi, Aikaterini Moullet, Barbara Henry, Hugues Métairon, Sylviane Marquis, Julien Descombes, Patrick Collino, Sebastiano Martin, François-Pierre J. Montoliu, Ivan Kussmann, Martin Wojcik, Jérôme Bowman, Gene L. Popp, Julius |
author_sort | Dayon, Loïc |
collection | PubMed |
description | BACKGROUND: Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The interrelated methionine, purine, and thymidylate cycles constitute the one-carbon metabolism that plays a critical role in the synthesis of DNA, neurotransmitters, phospholipids, and myelin. In this study, we tested the hypothesis that one-carbon metabolites beyond Hcy are relevant to cognitive function and cerebrospinal fluid (CSF) measures of AD pathology in older adults. METHODS: Cross-sectional analysis was performed on matched CSF and plasma collected from 120 older community-dwelling adults with (n = 72) or without (n = 48) cognitive impairment. Liquid chromatography-mass spectrometry was performed to quantify one-carbon metabolites and their cofactors. Least absolute shrinkage and selection operator (LASSO) regression was initially applied to clinical and biomarker measures that generate the highest diagnostic accuracy of a priori-defined cognitive impairment (Clinical Dementia Rating-based) and AD pathology (i.e., CSF tau phosphorylated at threonine 181 [p-tau181]/β-Amyloid 1–42 peptide chain [Aβ(1–42)] >0.0779) to establish a reference benchmark. Two other LASSO-determined models were generated that included the one-carbon metabolites in CSF and then plasma. Correlations of CSF and plasma one-carbon metabolites with CSF amyloid and tau were explored. LASSO-determined models were stratified by apolipoprotein E (APOE) ε4 carrier status. RESULTS: The diagnostic accuracy of cognitive impairment for the reference model was 80.8% and included age, years of education, Aβ(1–42), tau, and p-tau181. A model including CSF cystathionine, methionine, S-adenosyl-L-homocysteine (SAH), S-adenosylmethionine (SAM), serine, cysteine, and 5-methyltetrahydrofolate (5-MTHF) improved the diagnostic accuracy to 87.4%. A second model derived from plasma included cystathionine, glycine, methionine, SAH, SAM, serine, cysteine, and Hcy and reached a diagnostic accuracy of 87.5%. CSF SAH and 5-MTHF were associated with CSF tau and p-tau181. Plasma one-carbon metabolites were able to diagnose subjects with a positive CSF profile of AD pathology in APOE ε4 carriers. CONCLUSIONS: We observed significant improvements in the prediction of cognitive impairment by adding one-carbon metabolites. This is partially explained by associations with CSF tau and p-tau181, suggesting a role for one-carbon metabolism in the aggregation of tau and neuronal injury. These metabolites may be particularly critical in APOE ε4 carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0270-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5473969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54739692017-06-21 One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond Dayon, Loïc Guiraud, Seu Ping Corthésy, John Da Silva, Laeticia Migliavacca, Eugenia Tautvydaitė, Domilė Oikonomidi, Aikaterini Moullet, Barbara Henry, Hugues Métairon, Sylviane Marquis, Julien Descombes, Patrick Collino, Sebastiano Martin, François-Pierre J. Montoliu, Ivan Kussmann, Martin Wojcik, Jérôme Bowman, Gene L. Popp, Julius Alzheimers Res Ther Research BACKGROUND: Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The interrelated methionine, purine, and thymidylate cycles constitute the one-carbon metabolism that plays a critical role in the synthesis of DNA, neurotransmitters, phospholipids, and myelin. In this study, we tested the hypothesis that one-carbon metabolites beyond Hcy are relevant to cognitive function and cerebrospinal fluid (CSF) measures of AD pathology in older adults. METHODS: Cross-sectional analysis was performed on matched CSF and plasma collected from 120 older community-dwelling adults with (n = 72) or without (n = 48) cognitive impairment. Liquid chromatography-mass spectrometry was performed to quantify one-carbon metabolites and their cofactors. Least absolute shrinkage and selection operator (LASSO) regression was initially applied to clinical and biomarker measures that generate the highest diagnostic accuracy of a priori-defined cognitive impairment (Clinical Dementia Rating-based) and AD pathology (i.e., CSF tau phosphorylated at threonine 181 [p-tau181]/β-Amyloid 1–42 peptide chain [Aβ(1–42)] >0.0779) to establish a reference benchmark. Two other LASSO-determined models were generated that included the one-carbon metabolites in CSF and then plasma. Correlations of CSF and plasma one-carbon metabolites with CSF amyloid and tau were explored. LASSO-determined models were stratified by apolipoprotein E (APOE) ε4 carrier status. RESULTS: The diagnostic accuracy of cognitive impairment for the reference model was 80.8% and included age, years of education, Aβ(1–42), tau, and p-tau181. A model including CSF cystathionine, methionine, S-adenosyl-L-homocysteine (SAH), S-adenosylmethionine (SAM), serine, cysteine, and 5-methyltetrahydrofolate (5-MTHF) improved the diagnostic accuracy to 87.4%. A second model derived from plasma included cystathionine, glycine, methionine, SAH, SAM, serine, cysteine, and Hcy and reached a diagnostic accuracy of 87.5%. CSF SAH and 5-MTHF were associated with CSF tau and p-tau181. Plasma one-carbon metabolites were able to diagnose subjects with a positive CSF profile of AD pathology in APOE ε4 carriers. CONCLUSIONS: We observed significant improvements in the prediction of cognitive impairment by adding one-carbon metabolites. This is partially explained by associations with CSF tau and p-tau181, suggesting a role for one-carbon metabolism in the aggregation of tau and neuronal injury. These metabolites may be particularly critical in APOE ε4 carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-017-0270-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-17 /pmc/articles/PMC5473969/ /pubmed/28623948 http://dx.doi.org/10.1186/s13195-017-0270-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dayon, Loïc Guiraud, Seu Ping Corthésy, John Da Silva, Laeticia Migliavacca, Eugenia Tautvydaitė, Domilė Oikonomidi, Aikaterini Moullet, Barbara Henry, Hugues Métairon, Sylviane Marquis, Julien Descombes, Patrick Collino, Sebastiano Martin, François-Pierre J. Montoliu, Ivan Kussmann, Martin Wojcik, Jérôme Bowman, Gene L. Popp, Julius One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title | One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title_full | One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title_fullStr | One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title_full_unstemmed | One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title_short | One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond |
title_sort | one-carbon metabolism, cognitive impairment and csf measures of alzheimer pathology: homocysteine and beyond |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473969/ https://www.ncbi.nlm.nih.gov/pubmed/28623948 http://dx.doi.org/10.1186/s13195-017-0270-x |
work_keys_str_mv | AT dayonloic onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT guiraudseuping onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT corthesyjohn onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT dasilvalaeticia onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT migliavaccaeugenia onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT tautvydaitedomile onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT oikonomidiaikaterini onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT moulletbarbara onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT henryhugues onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT metaironsylviane onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT marquisjulien onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT descombespatrick onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT collinosebastiano onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT martinfrancoispierrej onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT montoliuivan onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT kussmannmartin onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT wojcikjerome onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT bowmangenel onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond AT poppjulius onecarbonmetabolismcognitiveimpairmentandcsfmeasuresofalzheimerpathologyhomocysteineandbeyond |